Abstract Submission Now Closed!
Are you an existing IASLC Member?
As an IASLC member and abstract presenter at WCLC 2024, not only will you have the opportunity to present your research to an international audience, you will also be eligible to apply for Education Awards or the International Mentorship Program.
Abstract Submission INFORMATION
April 5, 2024 (23:59 PDT)
Abstract Submission Deadline
May 29, 2024
Notification of Abstract
Acceptance
July 12, 2024 (23:59 PDT)
Presenting Author Registration
Deadline
July 31, 2024 (23:59 PDT)
Late-Breaking Abstract Deadline
July 23, 2024 (10:00 PDT)
Abstract Title Release (except LBA)
August 7, 2024 (23:59 PDT)
Late-Breaking Abstract
Notifications
August 14, 2024 (10:00 PDT)
Full Abstract Release Date
(Except for Embargoed Abstracts)
Abstract Submission Guidelines
To foster high-quality oral and written presentations at IASLC conferences, an implementation team will conduct a review of abstract titles and provide suggestions based on the IASLC Language Guide. We encourage you to review the Guide prior to submitting your abstract, to minimize later suggestions or edits and to help facilitate mutually respectful communication.
Word Limit: | 500 words (does not include title and authors) |
Title Word Limit: | 125 characters total (including spaces) |
Tables: | No limit; each table counts as 100 words |
Images: | 2 maximum; each image counts as 100 words |
Format(s): | Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. Higher resolution is acceptable and preferred. |
Language: | English |
Fee: | No submission fee |
Presenting Author Limit: | Authors can only be listed as the Presenting Author on two (2) abstracts but can be co-author on any number of abstracts. |
Number of Co-authors: | No limit of co-authors on any abstract. |
Encore Submission:
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.
Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form.
Publication:
Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.
Education Awards:
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 5, 2024 (23:59 PDT).
Abstract Submission Tracks
Risk Factors, Risk Reduction & Tobacco Control
Tumor Biology – Preclinical Biology
Tumor Biology – Translational Biology
Screening and Early Detection
Pulmonology and Staging
Pathology and Biomarkers
Early-Stage Non-small Cell Lung Cancer
Local-Regional Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer – Local Therapies
Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy
Metastatic Non-small Cell Lung Cancer – Immunotherapy
Metastatic Non-small Cell Lung Cancer – Targeted Therapy
Small Cell Lung Cancer and Neuroendocrine Tumors
Mesothelioma, Thymoma, and Other Thoracic Tumors
Multidisciplinary Care: Nursing, Allied Health and Palliative Care
Patient Advocacy
Global Health, Health Services, and Health Economics
Abstract Types Accepted
REGULAR ABSTRACT
Definition: Original scientific research that summarizes work done and major research findings.
Required sections for abstract submission:
Introduction
Methods
Results
Conclusion
CLINICAL TRIALS IN PROGRESS
(eligible for designation as poster or e-poster only)
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.
Required sections:
Introduction
Methods
Optional sections:
Results
Conclusion
CASE SERIES
(eligible for designation as poster or e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient. Must include a minimum of three (3), but preferably five (5) cases.
Required sections for abstract submission:
Introduction including selective literature review
Methods
Results
Conclusion
LATE-BREAKING ABSTRACT (LBA) SUBMISSION
Definition:
- LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines.
- LBA designation is not a means for extending the regular abstract deadline.
- Highly impactful studies that have complete data should be submitted as a regular abstract and will be considered for a prominent oral presentation based on scoring by the program committee.
- For abstracts that do not meet LBA requirements the authors will be given 48 hours to update the submitted data before the abstracts are re-classified as regular abstracts and rated based on the updated information.
Submission requirements:
Authors of LBA must submit a place holder abstract through the abstract portal by April 5, 2024 (23:59 PDT).
Required sections for LBA place holder, which must be submitted by the April 5, 2024 deadline:
Explanation of why the abstract qualifies as late-breaking
Introduction
Methods, including applicable endpoints
Types of anticipated analysis and data to be reported
LBA Eligibility Review:
The Scientific Program Committee will review LBA placeholder applications after the regular abstract submission deadline April 5, 2024. Authors of approved LBAs will be notified and advised on the processes for submitting final data by July 31, 2024. Authors of abstracts not being granted LBA status will be notified and given 48 hours to submit all available data before the abstract is re-classified as a regular abstract and included in the regular abstract review and scheduling process.
Required sections for final LBA, which must be submitted by July 31, 2024 (23:59 PDT):
Introduction
Methods, including applicable endpoints
Results
Conclusion
LBA abstracts not completed by the July 31 deadline will be automatically withdrawn and will not be considered for the meeting. Exceptions may be granted in exceptional circumstances. The Scientific Program Committee will review the final LBA and notify the authors of its disposition by August 7, 2024. Authors must accept/decline the presentation within 48 hours of notification.
- Explanation of why the abstract qualifies as late-breaking, including date for which the abstract will be updated prior to the LBA final submission deadline.
- Introduction
- Methods, including endpoints measured
- Types of anticipated analysis and data to be reported
Required sections for final LBA, which must be submitted by July 31, 2024:
Introduction
Methods, including applicable endpoints
Results
Conclusion
Review: The Scientific Program Committee will review LBA placeholder applications. Authors of approved LBAs will be notified and advised on deadlines and the processes for submitting final data by July 31, 2024. LBA abstracts not completed by this deadline will be automatically withdrawn and will not be considered for the meeting. The Scientific Program Committee will review the final LBA and notify the authors of its disposition by August 8, 2024.
Education Award INFORMATION
April 5, 2024 (23:59 PDT)
Education Awards
Application Deadline
May 29, 2024
Notification of Education Awards
The IASLC offers a variety of education and mentorship awards to help researchers from around the world attend the IASLC 2024 World Conference on Lung Cancer (#WCLC24). Award winners are determined by an international, multidisciplinary review committee comprised of IASLC members.
2024 EDUCATION, TOBACCO CONTROL AND SMOKING CESSATION, NAHP, PATIENT ADVOCATE AND MENTORSHIP AWARDS:
- Early Career Awards
- Developing Countries Education Award
- Nurse or Allied Health Professional Awards
- Early Career in Tobacco Control and Smoking Cessation Award
- Developing Countries in Tobacco Control and Smoking Cessation Award
- IASLC International Mentorship Program
- IASLC Patient Advocate Education Award
Become an IASLC Member
Unlock Exclusive Opportunities at WCLC 2024
- Save up to 200 USD on Conference Registration
- Eligibility for Education Awards
- Eligibility for International Mentorship Program
As an IASLC member, delegates can unlock exclusive discounts, securing savings of up to $200 on conference registration fees. Additionally, membership offers access to coveted Education Awards and participation in the esteemed International Mentorship Program. Seize this opportunity to not only join a global community of lung cancer research and treatment experts but also to enjoy unparalleled cost benefits and invaluable educational opportunities.